Roche : Phase III Study Of Columvi Combo Extends Survival In Relapsed Diffuse Large B-Cell Lymphoma
16/6 08:26
(RTTNews) - Roche (RHHBY) announced statistically significant and clinically meaningful results from its Phase III STARGLO study of Columvi (glofitamab) in combination with gemcitabine and oxaliplatin (GemOx) versus MabThera/Rituxan (rituximab) in combination with GemOx (R-GemOx)...